Product Update

Deltex Medical Group PLC
16 March 2006



                           Deltex Medical Group plc

              Liver surgery audit demonstrates benefits of CardioQ


16 March 2006 Deltex Medical Group plc ('Deltex Medical' or the 'Company'), the
AIM listed haemodynamic monitoring company, today announces the preliminary
findings from an audit of the use of the Company's CardioQ(TM) monitor in liver
surgery.

Major liver surgery carries with it the risk of severe blood loss requiring
transfusion of whole blood or elements derived from whole blood ('blood
products'). Patients undergoing liver surgery frequently experience
complications related to the need for transfusion that can markedly extend
length of stay.

Doctors and managers at a European teaching hospital undertook an audit of the
use of the CardioQ in ten patients undergoing major liver surgery and compared
the use of disposable equipment, whole blood and blood products for these
patients with historical averages.

Overall, use of whole blood and blood products was significantly less on average
for the monitored group. Cost savings, taking into account the cost of the
Deltex Medical probe and the reduction in whole blood, blood products and
ancillary equipment used, but excluding savings from length of stay reduction,
were approximately €3,500 per patient.

Deltex Medical's Chief Executive, Andy Hill, commented:

'This work in liver surgery represents a new and different approach to the use
of the CardioQ. In this application the primary goal is to safely manipulate a
patient's haemodynamic status in order to minimise blood loss and the resultant
need for blood transfusion.

'There are approximately 80,000 patients every year in Europe alone who could
benefit enormously from this approach if it were adopted as a standard of care,
and there is the additional potential for substantial cost savings at 
hospitals.'



For further information, please contact:-

Deltex Medical Group plc                                          01243 774 837
Nigel Keen, Chairman              [e-mail]
Andy Hill, Chief Executive        [e-mail]
Ewan Phillips, Finance Director   [e-mail]

Financial Dynamics
David Yates                       [e-mail]              0207 831 3113
John Gilbert                      [e-mail]



Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-


•   validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

•   proved that the CardioQ works in a wide range of surgical procedures

•   demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange